Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 15/20 | 0.56 |
| ▸ | ITGA4 | P13612 | 15/20 | 0.56 |
| ▸ | ITGB7 | P26010 | 7/20 | 0.56 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7429256 | 1.00 | ITGB1 (0.56) | ITGB1ITGA4ITGB7ITGA2L3MBTL1 | |
| SCHEMBL12889768 | 0.94 | ITGB1 (0.49) | ITGB1ITGA4ITGB7ITGA2NOS2 | |
| SCHEMBL3316636 | 0.94 | ITGB1 (0.49) | ITGB1ITGA4ITGB7ITGA2NOS2 | |
| SCHEMBL6638679 | 0.92 | L3MBTL1 (0.55) | ITGB1ITGA4ITGB7ITGA2L3MBTL1 | |
| SCHEMBL6585927 | 0.90 | ITGB1 (0.45) | ITGB1ITGA4ITGB7ITGA2L3MBTL1 | |
| SCHEMBL6580118 | 0.88 | ITGB1 (0.52) | ITGB1ITGA4ITGB7L3MBTL1ALDH1A1 | |
| SCHEMBL27541119 | 0.87 | NOS2 (0.43) | ITGB1ITGA4ITGB7ITGA2NOS2 | |
| SCHEMBL27541117 | 0.87 | NOS2 (0.43) | ITGB1ITGA4ITGB7ITGA2NOS2 | |
| SCHEMBL7432342 | 0.86 | L3MBTL1 (0.64) | ITGB1ITGA4ITGB7ITGA2L3MBTL1 | |
| SCHEMBL6639882 | 0.85 | ITGB1 (0.60) | ITGB1ITGA4ITGB7ITGA2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150209294-A1 | PHARMACEUTICAL COMPOSITION AND PROCESS | HOFFMANN-LA ROCHE INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150209294-A1 | PHARMACEUTICAL COMPOSITION AND PROCESS | HOFFMANN-LA ROCHE INC. | 2015-07-30 | — | — | US | disclosed |
| CN-100369888-C | N-alkanoylphenylalanine derivatives | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | CN | disclosed |
| US-20070184113-A1 | Pharmaceutical composition and process | CHATTERJI ASHISH | 2007-08-09 | — | — | US | disclosed |
| US-20070184113-A1 | Pharmaceutical composition and process | CHATTERJI ASHISH | 2007-08-09 | — | — | US | disclosed |
| WO-2007082809-A1 | PHARMACEUTICAL COMPOSITION AND PROCESS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| EP-1154993-B1 | THIOAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | disclosed |
| EP-1005445-B1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-05-26 | — | — | EP | disclosed |
| EP-1403247-A1 | N-Alkanoylphenylalanine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| US-6479666-B2 | ANTIINFLAMMATORY AGENTS | HOFFMAN-LA ROCHE INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020028933-A1 | Thioamide derivatives | HULL KENNETH GREGORY (US) | 2002-03-07 | — | — | US | disclosed |
| US-20020010338-A1 | PHENYL-KETO-IMIDAZOLIDINE THIOAMIDE DERIVATIVES | HULL KENNETH G (US) | 2002-01-24 | — | — | US | disclosed |
| EP-1154993-A1 | THIOAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-21 | — | — | EP | disclosed |
| US-20010041799-A1 | Diephenyl carbocyclic thioamide derivatives | HULL KENNETH G (US) | 2001-11-15 | — | — | US | disclosed |
| US-6288267-B1 | AROMATIC CARBOXY THIOAMIDES WITH AMIDES AS DRUGS TO COUNTERACT INFLAMMATION | HOFFMANN-LA ROCHE INC. | 2001-09-11 | — | — | US | disclosed |
| US-6229011-B1 | BINDING INHIBITORS BETWEEN VASCULAR ADHESION MOLECULE-1 AND ALPHA. BETA.INTEGRIN; USEFUL FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES SUCH AS MULTIPLE SCLEROSIS, ASTHMA, AND INFLAMMATORY BOWEL DISEASE | HOFFMAN-LA ROCHE INC. | 2001-05-08 | — | — | US | disclosed |
| CN-1281430-A | N-alkanoylphenylalanine derivatives | HOFFMANN LA ROCHE (CH) | 2001-01-24 | — | — | CN | disclosed |
| WO-2000048994-A1 | THIOAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-24 | — | — | WO | disclosed |
| EP-1005445-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010312-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028933-A1 | Thioamide derivatives | VCAM1, ICAM1, LTB4R | ITGB1 9/4885ITGA4 8/4885ITGB7 117/4885 |
| US-20020010338-A1 | PHENYL-KETO-IMIDAZOLIDINE THIOAMIDE DERIVATIVES | VCAM1, ICAM1, KCNA4 | ITGB1 34/4885ITGA4 17/4885ITGB7 181/4885 |
| US-20070184113-A1 | Pharmaceutical composition and process | DDC, DNPEP, TYR | ITGB1 4681/4885ITGA4 4042/4885ITGB7 2856/4885 |
| US-20150209294-A1 | PHARMACEUTICAL COMPOSITION AND PROCESS | DDC, DNPEP, TYR | ITGB1 4694/4885ITGA4 4028/4885ITGB7 3072/4885 |
| US-20010041799-A1 | Diephenyl carbocyclic thioamide derivatives | VCAM1, ICAM1, LTB4R | ITGB1 18/4885ITGA4 17/4885ITGB7 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.